Ticlopidin Ratiopharm

Ticlopidin-ratiopharm may be available in the countries listed below.

Ingredient matches for Ticlopidin-ratiopharm

Ticlopidine

Ticlopidine hydrochloride (a derivative of Ticlopidine) is reported as an ingredient of Ticlopidin-ratiopharm in the following countries:

• Belgium


• Czech Republic


• Germany


• Slovakia

International Drug Name Search

Apo-Chlorpropamide

Apo-Chlorpropamide may be available in the countries listed below.

Ingredient matches for Apo-Chlorpropamide

Chlorpropamide

Chlorpropamide is reported as an ingredient of Apo-Chlorpropamide in the following countries:

• Canada


• Vietnam

International Drug Name Search

Viracept

Viracept is a brand name of nelfinavir, approved by the FDA in the following formulation(s):

VIRACEPT (nelfinavir mesylate - powder; oral)

• 
  Manufacturer: AGOURON
  
  Approval date: March 14, 1997
  
  Strength(s): EQ 50MG BASE/SCOOPFUL ^[RLD]

VIRACEPT (nelfinavir mesylate - tablet; oral)

• 
  Manufacturer: AGOURON
  
  Approval date: March 14, 1997
  
  Strength(s): EQ 250MG BASE ^[RLD]


• 
  Manufacturer: AGOURON
  
  Approval date: April 30, 2003
  
  Strength(s): EQ 625MG BASE ^[RLD]

Has a generic version of Viracept been approved?

No. There is currently no therapeutically equivalent version of Viracept available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viracept. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  HIV protease inhibitors
  Patent 5,484,926
  Issued: January 16, 1996
  Inventor(s): Dressman; Bruce A. & Fritz; James E. & Hammond; Marlys & Hornback; William J. & Kaldor; Stephen W. & Kalish; Vincent J. & Munroe; John E. & Reich; Siegfried H. & Tatlock; John H. & Shepherd; Timothy A. & Rodriguez; Michael J.
  Assignee(s): Agouron Pharmaceuticals, Inc.
  HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
  
  Patent expiration dates:
  
  
  • October 7, 2013
    
  
  
  
  • April 7, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  HIV protease inhibitors
  Patent 5,952,343
  Issued: September 14, 1999
  Inventor(s): Dressman; Bruce A. & Fritz; James E. & Hornback; William J. & Kaldor; Stephen W. & Kalish; Vincent J. & Munroe; John E. & Reich; Siegfried Heinz & Tatlock; John H. & Shepherd; Timothy A. & Rodriguez; Michael J.
  Assignee(s): Agouron Pharmaceuticals, Inc.
  HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
  
  Patent expiration dates:
  
  
  • October 7, 2013
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
  
  
  
  • April 7, 2014
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
  Patent 6,162,812
  Issued: December 19, 2000
  Inventor(s): Dressman; Bruce A. & Fritz; James E. & Hammond; Marlys & Hornback; William J. & Kaldor; Stephen W. & Kalish; Vincent J. & Munroe; John E. & Reich; Siegfried Heinz & Tatlock; John H. & Shepherd; Timothy A. & Rodriguez; Michael J.
  Assignee(s): Agouron Pharmaceuticals, Inc.
  HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
  
  Patent expiration dates:
  
  
  • October 7, 2013
    
    ✓ 
    Patent use: TREATMENT OF HIV
  
  
  
  • April 7, 2014
    
    ✓ 
    Patent use: TREATMENT OF HIV
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Viracept Consumer Information (Drugs.com)
• Viracept Consumer Information (Wolters Kluwer)
• Viracept Powder Consumer Information (Wolters Kluwer)
• Viracept Consumer Information (Cerner Multum)
• Viracept Advanced Consumer Information (Micromedex)
• Viracept AHFS DI Monographs (ASHP)
• Nelfinavir Consumer Information (Wolters Kluwer)
• Nelfinavir Powder Consumer Information (Wolters Kluwer)
• Nelfinavir Consumer Information (Cerner Multum)
• Nelfinavir Advanced Consumer Information (Micromedex)
• Nelfinavir Mesylate AHFS DI Monographs (ASHP)

Nortin

Nortin may be available in the countries listed below.

Ingredient matches for Nortin

Nortriptyline

Nortriptyline hydrochloride (a derivative of Nortriptyline) is reported as an ingredient of Nortin in the following countries:

• Bangladesh

International Drug Name Search

Rhinostop

Rhinostop may be available in the countries listed below.

Ingredient matches for Rhinostop

Xylometazoline

Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of Rhinostop in the following countries:

• Russian Federation


• Switzerland

International Drug Name Search

Eto-GRY

Eto-GRY may be available in the countries listed below.

Ingredient matches for Eto-GRY

Etoposide

Etoposide is reported as an ingredient of Eto-GRY in the following countries:

• Germany

International Drug Name Search

Esotrax

Esotrax may be available in the countries listed below.

Ingredient matches for Esotrax

Esomeprazole

Esomeprazole is reported as an ingredient of Esotrax in the following countries:

• India

International Drug Name Search

Lobeline Harvest Pharm

Lobeline Harvest Pharm may be available in the countries listed below.

Ingredient matches for Lobeline Harvest Pharm

Lobeline

Lobeline hydrochloride (a derivative of Lobeline) is reported as an ingredient of Lobeline Harvest Pharm in the following countries:

• China

International Drug Name Search

Betametasone Dipropionato Ecobi

Betametasone Dipropionato Ecobi may be available in the countries listed below.

Ingredient matches for Betametasone Dipropionato Ecobi

Betamethasone

Betamethasone 17α,21-dipropionate (a derivative of Betamethasone) is reported as an ingredient of Betametasone Dipropionato Ecobi in the following countries:

• Italy

International Drug Name Search

Perebron

Perebron may be available in the countries listed below.

Ingredient matches for Perebron

Oxolamine

Oxolamine citrate (a derivative of Oxolamine) is reported as an ingredient of Perebron in the following countries:

• Chile


• Venezuela

Oxolamine phosphate (a derivative of Oxolamine) is reported as an ingredient of Perebron in the following countries:

• Chile


• Turkey


• Venezuela

International Drug Name Search